MAGE-A3 peptides presented by HLA class II molecules

US7049413B2 · kind B2 · utility

Assignee

• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Yi Zhang · Edison, US
• Pascal Chaux · Brussels, BE
• Thierry Boon-Falleur · Brussels, BE
• Pierre van der Bruggen · Brussels, BE

Key dates

• Filing date: May 18, 2001
• Grant date: May 23, 2006
• Expiry date: Sep 14, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.